Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | HTR1E | P28566 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133905 | 0.91 | HPGD (0.40) | CSNK2A2CSNK2BCSNK2A1GDAKDM4E | |
| Uric Acid SCHEMBL20141715 | 0.91 | GDA (0.57) | CSNK2A2CSNK2BCSNK2A1GDAKDM4E | |
| SCHEMBL10607692 | 0.76 | PDE4A (0.49) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL6189308 | 0.75 | HSD17B10 (0.44) | CSNK2A2CSNK2BCSNK2A1KDM4EHSD17B10 | |
| SCHEMBL6189307 | 0.75 | ALDH1A1 (0.45) | CSNK2A2CSNK2BCSNK2A1KDM4EHSD17B10 | |
| SCHEMBL15229038 | 0.74 | GDA (0.39) | GDAHSD17B10DAOTSHRCYP2C19 | |
| SCHEMBL4938974 | 0.74 | GDA (0.39) | GDAKDM4EHSD17B10ALDH1A1MAPT | |
| SCHEMBL28923035 | 0.74 | GDA (0.39) | GDAHSD17B10TSHRCYP2C19ACHE | |
| SCHEMBL923063 | 0.74 | MAPK10 (0.47) | KDM4EHSD17B10ALDH1A1MAPTHPGD | |
| SCHEMBL18125929 | 0.74 | GDA (0.35) | GDAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| US-20200046712-A1 | PROCESS FOR MAKING 1,3,7- TRIMETHYLURIC ACID WATER SOLUBLE SALTS OR CO-CRYSTALS AND THEIR USAGE IN DIETARY SUPPLEMENTS OR FUNCTIONAL FOODS FORMULATIONS | Arcadia Biotechnology Ltd. (CN) | 2020-02-13 | — | — | US | claimed |
| CN-106537145-A | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2017-03-22 | — | — | CN | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| WO-2013093099-A1 | STABILIZATION OF PEPTIDIC RADIOPHARMACEUTICALS USING URIC ACID OR DERIVATIVES THEREOF | PIRAMAL IMAGING SA (DE) | 2013-06-27 | — | — | WO | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12054768-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-06 | — | — | US | disclosed |
| EP-3538151-B1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INST BIOMEDICAL RES (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230051644-A1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2023-02-16 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20080275206-A1 | POLY(CARBONATE-CO-UREA) COPOLYMERS AND MELT TRANSESTERIFICATION METHOD OF PREPARING THESE COPOLYMERS | GENERAL ELECTRIC COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275209-A1 | POLY(CARBONATE-CO-UREA) COPOLYMERS AND MELT TRANSESTERIFICATION METHOD OF PREPARING THESE COPOLYMERS | GENERAL ELECTRIC COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| WO-2008024893-A2 | DERIVATIVES OF URIC AND THIOURIC ACID FOR OXIDATIVE STRESS-RELATED DISEASES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-1998004132-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH NITRIC OXIDE OR PEROXYNITRITE SCAVENGERS | THOMAS JEFFERSON UNIVERSITY (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046712-A1 | PROCESS FOR MAKING 1,3,7- TRIMETHYLURIC ACID WATER SOLUBLE SALTS OR CO-CRYSTALS AND THEIR USAGE IN DIETARY SUPPLEMENTS OR FUNCTIONAL FOODS FORMULATIONS | SLC16A7, SLC16A1, SLC16A8 | CSNK2A2 4569/4885CSNK2B 4649/4885CSNK2A1 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.